Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03536767 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of AG10 in Patients with Cardiomyopathy
A Phase 2 study of Amyloid Cardiomyopathy, sponsored by Eidos Therapeutics, a BridgeBio company.
- Active
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 9
- Study locations
NCT03536767: Active Phase 2 study of Amyloid Cardiomyopathy, sponsored by Eidos Therapeutics, a BridgeBio company.
NCT03536767 is a Phase 2 study of Amyloid Cardiomyopathy that is active but no longer recruiting, run by Eidos Therapeutics, a BridgeBio company. The registered enrollment target is 55 participants, below the 220-participant average among 3 other Amyloid Cardiomyopathy trials with a reported enrollment target (75% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03536767, a Phase 2 study of Amyloid Cardiomyopathy, is active but no longer recruiting, sponsored by Eidos Therapeutics, a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 9
- Study locations
Study Summary
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
Primary Outcome
Incidence of each treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG AG10
Study Locations (9)
California
- Stanford University - Palo Alto
- University of California San Francisco - San Francisco
Connecticut
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- Columbia University - New York
Oregon
- Oregon Health & Science University - Portland
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What the registry record for NCT03536767 still lists
NCT03536767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 220-participant average among 3 other Amyloid Cardiomyopathy trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Amyloid Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which AG10 is the first listed.
NCT03536767 lists 9 locations in 8 states (California, Connecticut, Illinois).
Frequently Asked Questions
What is clinical trial NCT03536767 about?
NCT03536767 is a clinical study titled "Open-Label Study of AG10 in Patients with Cardiomyopathy". This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
What is the current status of trial NCT03536767?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2018-08-08. Estimated completion is 2027-07.
What conditions does trial NCT03536767 study?
This clinical trial studies the following conditions: Amyloid Cardiomyopathy.
What interventions are being tested in trial NCT03536767?
The interventions under investigation include: AG10 (DRUG).
Who is sponsoring clinical trial NCT03536767?
This trial is sponsored by Eidos Therapeutics, a BridgeBio company, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03536767 being conducted?
This trial has 9 study locations across California, Connecticut, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloid Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise Training in Transthyretin Cardiac Amyloidosis
RECRUITING · NA
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI